occurrence of vein thrombosis has been shown. 10 This association may also be related to the thrombotic events in ISSHL.
Activation of protein C has a major role in the natural anticoagulation pathway. The activation process starts at the endothelial cell surface by thrombin-thrombomodulin complex and is enhanced by the endothelial cell protein C receptor (EPCR). A 23-bp insertion located at the third exon of the EPCR gene that alters the function of EPCR has been reported. This insertion, which slows the activation of protein C, is a possible thrombotic risk factor. 11 Decreased fibrinolytic activity due to increased levels of plasminogen activator inhibitor-1 (PAI-1) has been shown in deep vein thrombosis. Elevated plasma PAI-1 levels are associated with the 4G allele of a 4G/5G polymorphism located at -675 in the promoter region of the PAI-1 gene. The results of the previous studies showed that the 4G allele with FV 1691 A allele increases the risk for deep vein thrombosis. 12 Moreover, another study revealed that methylene tetrahydrofolate reductase 677 C-T (MTHFR I diopathic sudden sensorineural hearing loss (ISSHL) is a common disease associated with hearing loss, with an incidence of approximately 1 to 2/10 000 individuals annually. 1 Nevertheless, the etiology of sudden hearing loss is still unknown. The most common cause of sudden hearing loss appears to be impaired cochlear blood circulation, although the scientific basis of this assumption has not yet been proven. [2] [3] [4] In recent years, several inherited prothrombotic risk factors have been found. The 3 most common mutations reported in thrombosis, factor V 1691 G-A (FV Leiden), factor V 4070 A-G (HR2 haplotype), and prothrombin 20210 G-A (PT 20210 G-A) 5 , were studied in the Turkish population. [5] [6] [7] [8] [9] A significant association between the HR2 haplotype and the Impaired cochlear blood circulation has been suggested to cause sudden hearing loss. In this study, the role of factor V 1691 G-A (FV 1691 G-A), prothrombin 20210 G-A (PT 20210 G-A), methylene tetrahydrofolate reductase 677 C-T (MTHFR 677 C-T), factor V 4070 A-G (FV 4070 A-G), endothelial cell protein C receptor (EPCR) gene 23-bp insertion, and plasminogen activator inhibitor-1 (PAI-1) 4G/5G mutation was assessed. Fifty-three patients with idiopathic sudden sensorineural hearing loss and 80 individuals comprising the control group were included in this study. The frequency for FV 1691 A was 6.2% in the patient group and 3.7% in the control group, PT 20210 G-A was 1.2% in the patient group and 1.9% in the control group, and FV 4070 A-G was 7.5% in the patient group and 11.3% in the control group. The frequency of MTHFR 677 C-T was significantly higher in the patient group than in the control group, with a P value of .03. PAI-1-675 4G/5G polymorphism was found to be 71.2% and 69.8%, in the control group and the patient group, respectively. The EPCR 23-bp insertion was 0% in the control group and was found in 3 patients (3.7%), which needs further study.
Keywords: idiopathic sudden hearing loss, thrombotic risk factors, vascular impairment, EPCR 677 C-T) mutation was also a risk factor. Methylene tetrahydrofolate reductase, methylene tetrahydrofolate dehydrogenase, methionine synthase, methionine synthase reductase, cobalamin coenzyme, and cystathionine-B synthase are the enzymes that play a role in homocysteine metabolism. 13 A C-T polymorphism at nucleotide 677 in the MTHFR gene responsible for an alanine to valine substitution results in the synthesis of a thermolabile form of MTHFR that causes increased levels of homocysteine. 14 The homocysteine metabolism-related genes have been found to be associated with venous thrombosis 15, 16 and also with ISSHL. 17, 18 It has been reported that thromboembolic events play a role in ISSHL. In this study, the possible effects of these common thrombophilic mutations (factor V 1691 G-A, factor V 4070 A-G, and PT 20210 G-A) and MTHFR, EPCR, and PAI-1 gene mutations in ISSHL were investigated.
Materials and Methods
Genomic DNA was extracted from peripheral blood by a conventional phenol-chloroform method. Amplification of exon 13 of the factor V gene was performed, and PCR products were restricted with RsaI (New England Biolabs, Ipswich, Massachusetts). For the detection of EPCR gene 23-bp insertion/ deletion polymorphism 19 and for the amplification of PAI-1 gene, PCR was performed, and for the detection of 4G/5G polymorphism of the PAI-1 gene, BseLI (Fermentas, Vilnius, Lithuania) restriction enzyme digestion was performed. 12 Comparisons between the patients and the control group were analyzed with chi-square and Mann-Whitney U tests. Odds ratio and 95% confidence intervals as an estimate of the relative risk of the allele frequency were calculated for the entire study population. Differences with P values less than .05 were considered statistically significant. Allele frequencies were calculated by gene counting.
Results
The frequency of FV 1691 G-A mutation in ISSHL was found to be 6.2% in the patient group and 3.7% in the controls, PT 20210 G-A mutation was 1.2% in the patient group and 1.9% in the controls, and FV 4070 A-G mutation was 7.5% in the patient group and 11.3% in the controls. The frequency of MTHFR 677 C-T mutation was significantly higher in the patient group than in the control group. The EPCR 23-bp insertion was found to be 0% in the controls and 3.7% in the patients group, and PAI-1-675 4G/5G polymorphism was 71.2% and 69.8% in the control group and the ISSHL patient group, respectively. The findings of our results are shown in Table 1 .
Discussion
The most common cause of sudden hearing loss appears to be impaired cochlear blood circulation, although the scientific basis of this assumption has not been proven yet. Studies on the role of the prothrombotic risk factors in ISSHL were controversial. 1, 18 In a study assessing the correlation of prothrombotic risk factors, predominantly FV 1691 G-A and PT 20210 G-A, and the etiology of ISSHL, it has been suggested that PT 20210 G-A mutation is a significant risk factor for the occurrence of the disease, whereas FV 1691 G-A is not. 1 It has been reported that factor V 1691 A mutation is a significant risk factor for the occurrence of ISSHL; however, there are other studies that indicate PT 20210 G-A mutation to be a risk factor and not factor V mutation. 17 Our study revealed that factor V gene mutations (1691 G-A, the unpublished 4070 A-G mutation, and PT 20210 G-A mutations) are not risk factors for the occurrence of ISSHL. Five patients carrying HR2 haplotype also had MTHFR 677 T, whereas 4 patients also carried PAI-1 gene 4G5G allele with HR2 haplotype. PAI-1-675 4G allele was common in both the control and the patient groups, but it was not statistically important.
Recently, MTHFR gene 677 C-T mutation has been found to be associated with sudden hearing loss. 17, 18 This mutation was very common in our patient group, and heterozygosity was significantly important, with a P value of .03. One patient carried FV 1691 A, FV 4070 G, MTHFR 677 T, R1R2 allele along with 4G5G allele of the PAI-1 gene.
It is well known that there is also a quite firm link between ISSHL and infection. Endothelial cell protein C receptor may be a chain in this link. 20 As EPCR gene 23-bp insertion allele is very rare in general population, identification of 3 individuals with this deletion in our patient group supports a probable link between infection and ISSHL. Soluble form of EPCR gene increases in carriers of this rare mutation and in individuals with a specific haplotype. [21] [22] [23] Hence, this point needs further attention in ISSHL (Table 1 ).
In conclusion, these gene polymorphisms may be considered risk factors for ISSHL; however, further studies based on larger series of patients, including genomic analysis of multiple inherited prothrombotic factors, are needed to assess the role of prothrombotic factors thoroughly in the etiopathogenesis of ISSHL. NOTES: ISSHL = idiopathic sudden sensorineural hearing loss; OR = odds ratio; CI = confidence interval; FV = factor V; PT = prothrombin; MTHFR = methylene tetrahydrofolate reductase; EPCR = endothelial cell protein C receptor; PAI-1 = plasminogen activator inhibitor-1.
